(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Until recently, the UN was on track to meet its target of ending AIDS as a public health threat by 2030. But with the U.S.

DAR ES SALAAM: TANZANIA National Coordinating Mechanism (TNCM) has reaffirmed its commitment to ensure the Global Fund ...

Devastating funding cuts from international donors are hitting countries hardest affected by HIV — but many are showing ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they live ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite ...

Global Fund notes that the US has contributed more than $26.31 billion to date and pledged up to $6 billion for the Seventh ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...